Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226783 · ClinicalTrials.gov registry record · Phase 1
D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects
A Phase 1 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02226783 is a Phase 1 study that has completed, run by Ardelyx. The registered enrollment target is 37 participants.
The verdict
NCT02226783, a Phase 1 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
Study to evaluate the effect of intake of food in comparison to fasting condition on pharmacodynamics of AZD1722 following a twice-daily administration of AZD1722 tablet formulation
Interventions
- DRUG AZD1722 salt tablet
- DRUG AZD1722 free base tablet
- DRUG AZD1722 free base tablet + Omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226783
The ClinicalTrials.gov registry entry for NCT02226783 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AZD1722 salt tablet is the first listed.
NCT02226783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02226783 about?
NCT02226783 is a clinical study titled "D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects". Study to evaluate the effect of intake of food in comparison to fasting condition on pharmacodynamics of AZD1722 following a twice-daily administration of AZD1722 tablet formulation
What is the current status of trial NCT02226783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT02226783?
The interventions under investigation include: AZD1722 salt tablet (DRUG), AZD1722 free base tablet (DRUG), AZD1722 free base tablet + Omeprazole (DRUG).
Who is sponsoring clinical trial NCT02226783?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.